Pricing & Reimbursement
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.
Management updated investors on M&A strategy, US drug pricing reform and R&D investment.
In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private.
CEO Michel Vounatsos and US president Alisha Alaimo outlined plans to overcome the Alzheimer’s drug’s launch challenges and hinted at lower sales expectations at a Morgan Stanley investor event.
Big pharma leaders warn of steep cuts to R&D and US jobs if US drug pricing reform legislation paves the way for direct government price negotiations.
The approval of China's second CAR-T therapy has come amid reimbursement challenges, despite the pricing of its direct competitor being much lower than in the US. Chinese developers are pinning their hopes on rapid domestic market expansion via commercial insurance tie-ups as other CAR-Ts move through local development.
A price has finally been agreed for Novartis's small interfering RNA therapy and over the next three years, NHS England now expects to treat about 300,000 patients at high risk of a second cardiovascular event with inclisiran.
Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.
It is not only gene therapy companies that have found European payers hard to convince of the value of their products. Amarin’s proposed European pricing may lead to another US company exit.
The number of drugs included on formulary exclusion lists in the US has surpassed more than 400 at the top three PBMs, representing dramatic growth from just five years ago. Express Scripts recently revealed its 2022 exclusions.
The proprietary carbidopa/levodopa formulation increased good ON time with fewer doses versus immediate-release levodopa. A post-hoc analysis also showed 1.55 hours more ON time per dose.
Ascendis’s growth hormone deficiency drug Skytrofa will offer a convenience advantage as a weekly injectable. But the label does not clearly delineate superiority shown in a Phase III trial.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.